OrbiMed Advisors MNMD Position
Active7-Fund ConvergenceOrbiMed Advisors increased their position in Mind Medicine Inc. (MNMD) in Q4 2025, holding $16.4M worth of shares across 1,226,700 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
MNMD is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Mind Medicine Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Full company profile →OrbiMed Advisors MNMD Position History
Frequently Asked Questions
Does OrbiMed Advisors own MNMD?
Yes. As of Q4 2025, OrbiMed Advisors holds 1,226,700 shares of Mind Medicine Inc. (MNMD) valued at $16.4M. This data comes from their SEC 13F filing.
How many hedge funds own MNMD?
7 specialist biotech hedge funds currently hold MNMD, including Driehaus Capital, Avoro Capital Advisors, Deep Track Capital and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy MNMD?
OrbiMed Advisors's position in MNMD was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's MNMD position increasing or decreasing?
OrbiMed Advisors increased their MNMD position in the most recent quarter, adding 858,876 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
MNMDCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →